Multiple Myeloma

Response to treatment with a regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was greater and minimal residual disease (MRD) was achieved more frequently compared with a regimen of lenalidomide plus dexamethasone (Rd) in the first randomized phase 3 clinical trial dedicated to frail, transplant-ineligible patients with newly diagnosed multiple myeloma.

This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.

The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.

Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.

Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy.

A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers.

Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients.

Final analysis of ICARIA-MM demonstrated a 6.9-month improvement in survival with Isa-Pd compared to Pd alone in RRMM patients.

Meta-analysis of whole-body MRI versus FDG PET/CT to assess treatment response in MM may suggest a complementary benefit when utilizing both modalities.